Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-to-Treat Chronic Lymphocytic Leukaemia
CAMBRIDGE, England–(BUSINESS WIRE)– AstraZeneca and its haematology Centre of Excellence, Acerta Pharma, today announced preliminary results from the Phase I/II ACE-CL-001clinical trial of acalabrutinib in...